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IgA nephropathy (IgAN) is the most common form of glomerular disease worldwide and is associated with a poor prognosis, resulting in end-stage kidney disease (ESKD) in approximately 40% of cases within 20--30 years \[[@CR1]--[@CR3]\]. Patients can present with a range of signs and symptoms, from asymptomatic microscopic haematuria to macroscopic haematuria and/or proteinuria. Currently, no IgAN-specific therapies are available; therefore, development of a curative treatment and strategies for early diagnosis and treatment are urgently needed. Although the prognostic and predictive values of several markers have been discussed elsewhere, we recently developed a highly sensitive and specific diagnostic method as well as assessment of disease activity and prognosis by measuring serum levels of aberrantly glycosylated serum IgA1 and related IgA immune complexes. In this review, we focus on potential clinical applications of these biomarkers.

Limitations of renal biopsy and proteinuria for assessment of disease activity {#Sec2}
==============================================================================

The poor prognosis of IgAN is partly due to delayed diagnosis. Renal biopsy is the gold standard for diagnosis as well as assessment of disease activity and prognosis in patients with IgAN. However, the pathological findings differ according to the time point of renal biopsy during the long clinical course of IgAN \[[@CR1], [@CR2]\]. Different timing of intervention for renal biopsy may yield variations in pathological severity and chronicity on renal biopsy. Moreover, renal biopsy is not frequently performed because of procedural risks and/or limitations of medical insurance coverage. In fact, renal biopsy is not recommended for patients with isolated hematuria or mild proteinuria in Western countries, where renal biopsy is performed for those who develop increasing proteinuria or worsening renal function \[[@CR4]\].

Thus, renal biopsy provides information regarding transient conditions and has limited ability to provide an accurate assessment of disease activity. Furthermore, even if biopsy is performed during early stages of IgAN, pathological findings may be inconclusive, and it may be difficult to establish a prognosis. Moreover, in patients with IgAN accompanied by mild proteinuria with mild histological lesions at the time of renal biopsy, progression of proteinuria is observed in approximately 30--40% of cases \[[@CR3], [@CR5], [@CR6]\]. Thus, novel noninvasive biomarkers are needed for evaluation of real-time disease activity.

The degree of proteinuria is an important prognostic factor in IgAN and other renal diseases \[[@CR7], [@CR8]\], and many clinical studies have reported analysis of kidney function and proteinuria as endpoints in renal disease \[[@CR9], [@CR10]\]. Therefore, many clinical guidelines recommend therapeutic indication based on the degree of proteinuria \[[@CR11], [@CR12]\]. However, it is difficult to distinguish proteinuria from acute glomerular inflammatory lesions, such as cellular crescents or burned-out sclerotic glomerulus, in patients with IgAN. In general, IgAN may have a long chronic course with a mixture of acute inflammatory lesions and common pathway-based chronic lesions \[[@CR13]\], and proteinuria must be derived from both types of lesions. Accordingly, it is difficult to qualitatively discriminate proteinuria at the acute and chronic phases, and proteinuria-based assessment of disease activity is limited.

Based on this background, activity assessment methods other than renal biopsy and urinalysis are needed. In addition to assessment of disease activity, a simple and safe method for early diagnosis using valid biomarkers based on the pathogenesis of IgAN should be established.

Pathogenic importance of aberrantly glycosylated IgA1 in IgAN {#Sec3}
=============================================================

IgA in glomerular deposits is exclusively of the IgA1 subclass, and levels of the polymeric form of IgA1 are elevated in the serum of patients with IgAN \[[@CR14]--[@CR16]\]. Galactose deficiency of *O*-linked glycans in the hinge region of IgA1 is the beginning of a sequence of events that may lead to renal injuries. This galactose-deficient IgA1 (Gd-IgA1) consists of terminal *N*-acetylgalactosamine (GalNAc) or sialylated GalNAc \[[@CR17]--[@CR19]\]. Normal serum IgA1 is thought to contain little or no galactose-deficient *O*-glycans \[[@CR20]\] (Fig. [1](#Fig1){ref-type="fig"}), but some *O*-glycans of circulatory IgA1 in healthy individuals are galactose-deficient \[[@CR21]\]. In recent years, an increase in serum Gd-IgA1 levels in patients with IgAN was quantitatively confirmed for the first time by Moldoveanu et al. using *Helix aspersa* agglutinin lectin, which recognizes GalNAc residues \[[@CR22]\]. Analysis of immortalized IgA1-secreting cells derived from the circulation of patients with IgAN and healthy controls has shown that Gd-IgA1 is related to decreased activity of core 1 β1,3-galactosyltransferase (C1GalT1) and elevated activity of α-2,6-sialyltransferase 2 (ST6GalNAc-II) \[[@CR23]\]. Recent studies have shown that these enzymatic activities may be regulated by genetic mechanisms and dysregulation of mucosal immunity \[[@CR24]--[@CR26]\]. Mucosal infections, such as tonsillitis and upper respiratory infections, are associated with exacerbation of urinary abnormalities in patients with IgAN. In fact, Gd-IgA1-dependent modulation of C1GalT1 and ST6GalNAc-II is induced by interleukin (IL)-6 and IL-4 \[[@CR26]\]. Importantly, Toll-like receptor (TLR) 9 plays a key role in the progression of IgAN \[[@CR27], [@CR28]\], and overexpression of tonsillar TLR9 is correlated with the production of Gd-IgA1 \[[@CR29]\]. Furthermore, repeated TLR9 activation induces tonsillar expression of a proliferation-inducing ligand (April), which participates in the generation and survival of antibody-producing plasma cells, resulted in production of Gd-IgA1 \[[@CR30]\].

Fig. 1Structure of IgA1 and synthesis of IgA1 *O*-glycans. IgA1 has *O*-glycans located in the unique hinge region between constant-region domains 1 and 2 of the heavy chain. Serum levels of IgA1 with galactose-deficient glycans (Gd-IgA1) are elevated in patients with IgA nephropathy. The *Helix aspersa* agglutinin lectin and Gd-IgA1-specific autoantibodies recognize the galactose-deficient GalNAc

Previous reports have indicated that glomerular IgA1 in IgAN is aberrantly glycosylated \[[@CR31], [@CR32]\]. A fraction of Gd-IgA1 from the glomerular deposits is excreted into the urine and thus represents a disease-specific marker of IgAN. Urinary excretion of Gd-IgA1 discriminates patients with IgAN from patients with other proteinuric renal diseases \[[@CR33]\]. Furthermore, the level of urinary Gd-IgA1 is correlated with proteinuria in patients with IgAN. Urinary Gd-IgA1 thus may represent a disease-specific marker of IgAN. We recently established a novel lectin-independent method exploiting monoclonal antibody (KM55 mAb) for measuring serum levels of Gd-IgA1 \[[@CR34]\]; this method could be used worldwide for standardized measurement of serum Gd-IgA1 (Immuno-Biological Laboratories Co., Ltd.). In addition, we verified glomerular Gd-IgA1 was specifically detected in IgAN \[[@CR35]\]. Further studies are ongoing to establish a measurement system for urinary Gd-IgA1 using KM55 mAb.

Essential role of Gd-IgA1-specific antibodies {#Sec4}
=============================================

There is an increasing evidence that Gd-IgA1 has a pivotal role in the pathogenesis of IgAN \[[@CR36], [@CR37]\]. Serum Gd-IgA1 levels in relatives were elevated compared with those in normal individuals who were not blood relatives, regardless of the absence of nephropathy \[[@CR38]\]. In vitro, Gd-IgA1-containing immune complexes, but not Gd-IgA1 alone, induces the proliferation of mesangial cells \[[@CR39]\]. Furthermore, the concentration of immune complexes containing Gd-IgA1 is increased in the blood and urine of patients with IgAN \[[@CR40]--[@CR42]\]. Thus, these facts implied that additional pathogenic hits are necessary in the pathogenesis of IgAN. Gd-IgA1 in the serum of patients with IgAN is found exclusively within immune complexes bound to IgG or IgA1 antibodies. IgG autoantibodies recognize glycan-containing epitopes on Gd-IgA1 (Fig. [1](#Fig1){ref-type="fig"}) and exhibit unique features in the complementarity-determining region 3 of the variable region of their heavy chains \[[@CR43]\]. Furthermore, serum levels of Gd-IgA1-specific IgG autoantibodies are correlated with disease severity, as assessed by the magnitude of proteinuria \[[@CR43]\]. The onset and progression of IgAN is believed to require Gd-IgA1 (Hit 1), as well as endogenous anti-glycan antibodies (Hit 2) and subsequent immune complexes formation (Hit 3) and glomerular deposition (Hit 4; Fig. [2](#Fig2){ref-type="fig"}) \[[@CR36]\].

Fig. 2Hypothesis for the pathogenesis of IgA nephropathy. Synthesis of IgA1 with some *O*-glycans deficient in galactose (autoantigen) is elevated. Gd-IgA1 is present in the circulation at increased levels (Hit 1). This immunoglobulin is recognized by unique circulating anti-glycan autoantibodies (Hit 2). This process results in the formation of pathogenic IgA1-containing circulating immune complexes (Hit 3), some of which deposit in the glomeruli and induce renal injury (Hit 4). Upstream factors are likely involved in abnormal mucosal/innate immune responses characteristic for patients with IgA nephropathy

Gd-IgA1 and its related immune complexes as biomarkers for disease activity of IgAN {#Sec5}
===================================================================================

The above-described clinical findings suggested that Gd-IgA1 and its related immune complexes containing anti-glycan autoantibodies are essential effector molecules in pathogenesis of IgAN. Recent studies have demonstrated that increased serum Gd-IgA1 levels are associated with exacerbation of proteinuria and a greater risk of deterioration of renal function in IgAN \[[@CR44]\]. In addition, the combination of high serum Gd-IgA1 levels and circulating levels of advanced oxidation protein products is correlated with a more rapid decline in estimated glomerular filtration rate, suggesting that oxidative stress linked to Gd-IgA1 may be involved in the pathogenesis of IgAN \[[@CR45]\]. Although these reports did not analyze serum levels of IgA1-containing immune complexes, the serum levels of Gd-IgA1-specific IgG autoantibodies have been found to be correlated with disease severity \[[@CR43]\]. Furthermore, Berthoux et al. reported that serum levels of Gd-IgA1-specific IgG and IgA autoantibodies at the time of biopsy are significantly associated with progression of IgAN towards dialysis or death \[[@CR46]\]. Although a prognostic biomarker for recurrence after renal transplant is lacking in patients with IgAN, Gd-IgA1-specific IgG autoantibody level is associated with higher risk of recurrence \[[@CR47]\]. These findings further confirmed the multi-hit hypothesis as the pathogenic model of IgAN \[[@CR36]\] and indicated that evaluation of serum levels of the autoantigen (Gd-IgA1) and autoantibodies (IgG or IgA subclass) should be required as biomarkers of IgAN.

To evaluate therapeutic efficacy, we measured changes in serum levels of Gd-IgA1 before and after tonsillectomy. Cases with IgAN who showed significant decreases in serum Gd-IgA1 levels after tonsillectomy achieved significantly better improvement in hematuria \[[@CR29]\]. Moreover, serum levels of Gd-IgA1 and IgA-IgG IC were examined before and after tonsillectomy with steroid pulse therapy \[[@CR48]\]. Cross-sectional analysis revealed that the amounts of hematuria and proteinuria were significantly associated with serum levels of Gd-IgA1 and levels of IgA-IgG immune complexes \[[@CR48]\]. These non-invasive biomarkers for disease activity may be useful for guiding therapeutic approaches in the future.

Gd-IgA1 and its related immune complexes as biomarkers for the diagnosis of IgAN {#Sec6}
================================================================================

Moldoveanu et al. first investigated the quantification of serum levels of Gd-IgA1 as a diagnostic test \[[@CR22]\]. By receiver operating characteristic curve analysis, the serum level of Gd-IgA1 that provided 0.77 sensitivity had a specificity of 0.90 to distinguish patients with IgAN from healthy controls. We recently reported that serum levels of IgA, Gd-IgA1, Gd-IgA1-specific IgG, and Gd-IgA1-specific IgA were elevated in patients with IgAN compared with those of healthy controls and patients with other renal diseases \[[@CR49]\]. Gd-IgA1-specific IgG showed the best performance for the diagnosis of IgAN, with a sensitivity of 89% and specificity of 92%. Although those biomarkers may be useful for the diagnosis of IgAN, there is substantial overlap in serum levels of individual biomarkers between patients with IgAN, other renal diseases, and healthy controls \[[@CR49]\]. Consequently, no single biomarker was sufficiently specific for IgAN. These data suggested that a panel of such serum biomarkers may be helpful to differentiate IgAN from other glomerular diseases. In addition, other related markers, such as urinary Gd-IgA1 and IgG-IgA immune complexes, may be better to include in larger cohorts. Importantly, a multicenter trial of the diagnostic use of the panel of biomarkers has already been initiated in Japan.

Gd-IgA1 and its related immune complexes as biomarkers for early screening of IgAN {#Sec7}
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In Japan, annual checkups, including urine analysis, are performed beginning in childhood. About 75% of Japanese patients with IgAN are initially identified through chance hematuria. Although hematuria must be an initial manifestation of IgAN, glomerular injury leading to hematuria may precede that leading to persistent proteinuria. Thus, epidemiological studies assessing risk factors for chronic kidney disease have indicated that hematuria is a risk factor for proteinuria \[[@CR7], [@CR50]\]. Renal biopsy is not recommended for patients presenting with isolated hematuria. Early diagnosis and early intervention are essential to increase the chance of clinical remission \[[@CR51]\]. However, there are still many patients who show delayed intervention of therapy, resulting in deterioration of renal function. Therefore, these biomarkers may be applicable for secondary screening of examinees with hematuria in general checkups. Multicenter trials of early screening for patients with hematuria have already been started using a panel of biomarkers in Japan. Hematuria generally occurs prior to proteinuria in IgAN, and new screening systems with these biomarkers may dramatically change the importance of hematuria screening.

Conclusion {#Sec8}
==========

IgAN is the most common form of glomerular disease worldwide and is associated with a poor prognosis. Specific curative treatment strategies are needed for the management of IgAN. Emerging evidence has indicated that Gd-IgA1 and Gd-IgA1-containing immune complexes are essential effector molecules of IgAN. As discussed in this review, recent clinical and experimental studies have emphasized that Gd-IgA1 and Gd-IgA1-specific autoantibodies are prospective biomarkers for diagnostic and disease activity assessment in IgAN. Several clinical studies testing novel medications for IgAN are ongoing worldwide. Noninvasive and real-time examinations with such biomarkers on the basis of pathogenesis, as alternatives to renal biopsy, are critical for determining treatment efficacy and disease activity. Moreover, for the early screening of potential IgAN with isolated hematuria, those biomarkers may be applicable for early intervention and result in reduced risk of deterioration of renal function (Fig. [2](#Fig2){ref-type="fig"}).
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